Ovid Therapeutics Inc.

OVID · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders6.7%

Institutions80.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$7.25M	$566000	$391695	$1.50M	$208.38M	$12.62M	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$42.44M	-$61.88M	-$59.28M	-$55.55M	$124.21M	-$81.43M	-$61.41M	-$52.93M	-$65.01M
Operating income as a percentage of revenue.	-585.2%	-10933.7%	-15134.6%	-3696.4%	59.6%	-645.4%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$17.40M	-$26.40M	-$52.34M	-$54.17M	$122.83M	-$81.04M	-$60.46M	-$51.98M	-$64.81M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-232.70	$-366.70	$-0.74	$-0.77	$1.78	–	$-1.00	$-2.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-232.70	$-366.70	$-0.74	$-0.77	$1.76	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$13.15M	$26.30M	$27.04M	$44.87M	$187.80M	$72.03M	$41.90M	$36.49M	$87.13M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$150.93M	$92.17M	$144.03M	$155.27M	$194.54M	–	$80.84M	$47.65M	$89.46M
Everything the company owes — debt, unpaid bills, and other obligations.	$20.27M	$23.94M	$56.23M	$22.99M	$14.80M	–	$10.82M	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$130.66M	$68.23M	$87.80M	$132.27M	$179.75M	–	$70.02M	$38.81M	$83.44M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$38.30M	-$56.00M	-$45.80M	-$55.20M	$118.60M	-$51.58M	-$51.09M	-$45.56M	-$31.47M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$0	$71000	$40308	$1.22M	$184008	$127240	$57156	$33871	$38907
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$38.30M	-$56.07M	-$45.84M	-$56.42M	$118.42M	-$51.71M	-$51.15M	-$45.59M	-$31.51M

	You	Peer avg
Revenue Growth	-88.3%	+260.0%
ROE	-26.0%	-147.1%

Ovid Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison